NCT05650619 Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
| NCT ID | NCT05650619 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan |
| Condition | Focal Segmental Glomerulosclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-12-08 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2022-12-08 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinvigorated the scientific community to develop a collaborative community to advance research into the epidemiology, mechanisms, interventions, and outcomes. The purpose of RESOLVE is to gather a group of people with FSGS and MCD that have had or will have a kidney transplant to create a bank of information and biospecimens so researchers can more effectively study these diseases.
Eligibility Criteria
Inclusion Criteria: * Retrospective non-consented participant group had a transplant from the year 2000 and onward. * Diagnosis of FSGS or MCD in the native kidney (prior to transplant). Exclusion Criteria: * Pathologic diagnosis other than FSGS or MCD * FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)
Contact & Investigator
Eloise Salmon, MD
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT05650619 clinical trial?
This trial is open to participants of all sexes, studying Focal Segmental Glomerulosclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05650619 currently recruiting?
Yes, NCT05650619 is actively recruiting participants. Contact the research team at asboggs@med.umich.edu for enrollment information.
Where is the NCT05650619 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT05650619 clinical trial?
NCT05650619 is sponsored by University of Michigan. The principal investigator is Eloise Salmon, MD at University of Michigan. The trial plans to enroll 300 participants.